Homology Medicines Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	6.2yrs

Recent management updates

Recent updates

CEO

Homology Medicines has no CEO, or we have no data on them.

Board Members

Name	Position	Tenure	Compensation	Ownership
Saswati Chatterjee	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
Steven S. Gillis	Independent Director	8.2yrs	US$69.06k	0% $ 0
Matthew Patterson	Independent Director	6.2yrs	US$68.56k	0% $ 0
Beverly Davidson	Chairman of Scientific Advisory Board	6.2yrs	no data	no data
Mary Thistle	Independent Director	6yrs	US$76.06k	0% $ 0
Mason Freeman	Member of Scientific Advisory Board	no data	no data	no data
Morton Cowan	Member of Scientific Advisory Board	no data	no data	no data
Stephen Elledge	Member of Scientific Advisory Board	no data	no data	no data
Arthur Tzianabos	Chairman of the Board	7.9yrs	US$1.67m	0.22% $ 120.4k
Jeffrey Poulton	Lead Independent Director	3.7yrs	US$68.56k	0% $ 0
Alise Reicin	Independent Director	4.7yrs	US$68.22k	0% $ 0
Hans-Peter Kiem	Member of Scientific Advisory Board	no data	no data	no data

6.2yrs

Average Tenure

62yo

Average Age

Experienced Board: 0T6G's board of directors are considered experienced (6.2 years average tenure).

Homology Medicines Management

Management criteria checks 1/4

Key information

Recent management updates

Insufficient new directors

Insufficient new directors

Insufficient new directors

Homology Medicines, Inc. Appoints Albert Seymour as Chief Executive Officer

Insufficient new directors

Homology Medicines, Inc., Annual General Meeting, Jun 15, 2022

Recent updates

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from NASDAQ Composite Index

Full year 2023 earnings released: US$1.95 loss per share (vs US$0.087 loss in FY 2022)

Insufficient new directors

Q32 Bio Inc. entered into a definitive merger agreement to acquire Homology Medicines, Inc. (NasdaqGS:FIXX) for approximately $200 million in a reverse merger transaction.

Third quarter 2023 earnings released: US$0.57 loss per share (vs US$0.59 loss in 3Q 2022)

Homology Medicines, Inc. Approves Reduction in Workforce

New major risk - Revenue and earnings growth

Homology Medicines Announces First Data from IND-Enabling Studies with GTx-Mab Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, At the ASGCT Annual Meeting

First quarter 2023 earnings released: US$0.50 loss per share (vs US$1.61 profit in 1Q 2022)

Full year 2022 earnings released: US$0.087 loss per share (vs US$1.73 loss in FY 2021)

Homology Medicines, Inc. Provides Update on pheEDIT and juMPStart Clinical Trials

No longer forecast to breakeven

No longer forecast to breakeven

Third quarter 2022 earnings released: US$0.59 loss per share (vs US$0.54 loss in 3Q 2021)

Insufficient new directors

Insufficient new directors

Homology Medicines, Inc. Appoints Albert Seymour as Chief Executive Officer

Forecast to breakeven in 2022

First half 2022 earnings released: EPS: US$1.10 (vs US$0.56 loss in 1H 2021)

Homology Medicines Announces Optimized, in Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy

Insufficient new directors

Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from Russell 2000 Dynamic Index

Homology Medicines, Inc. Announces FDA Lifted Clinical Hold on Phenix Gene Therapy Trial for Pku

First quarter 2022 earnings released: EPS: US$1.61 (vs US$0.021 loss in 1Q 2021)

Robbins Geller Rudman & Dowd LLP Announces That Homology Medicines, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

Homology Medicines, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Homology Medicines, Inc. Announces Promotion of Albert Seymour to President

Homology Medicines, Inc. Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU

Homology Medicines Announces Multiple Presentations on HMI-203 Gene Therapy Candidate for the Treatment of Hunter Syndrome

Insufficient new directors

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.62 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.54 loss per share (vs US$0.78 loss in 2Q 2020)

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from Russell 2500 Growth Index

Homology Medicines, Inc. Announces Presentations on Its Expanding Genetic Medicines Platform and Internal GMP Manufacturing

First quarter 2021 earnings released: US$0.021 loss per share (vs US$0.78 loss in 1Q 2020)

Full year 2020 earnings released: US$2.80 loss per share (vs US$2.47 loss in FY 2019)

Revenue misses expectations

Novartis Elects to Terminate the Collaboration and License Agreement with Homology Medicines, Inc

Homology Medicines, Inc. Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (Pku) and Hunter Syndrome (Mps Ii)

Homology Medicines, Inc. announced that it expects to receive $60 million in funding from Pfizer Inc.

Homology Medicines Announces Upcoming Oral Presentation on pheNIX Gene Therapy Clinical Trial for Adults with PKU

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from S&P Biotechnology Select Industry Index

CEO

Board Members

Average Tenure

Average Age